EG24228A - Tartrate salts of 5,8,18-trizatetracyclo[010.3.1.0.0]hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof - Google Patents

Tartrate salts of 5,8,18-trizatetracyclo[010.3.1.0.0]hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof

Info

Publication number: EG24228A
Authority: EG; Egypt
Prior art keywords: trizatetracyclo; pentaene; hexadeca; pharmaceutical compositions; tartrate salts
Prior art date: 2001-05-14

Application number

EG20020483A

Other languages

English (en)

Inventor

Bogle E David

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-14

Filing date

2002-05-13

Publication date

2008-11-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23117845&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EG24228(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-05-13 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2008-11-10 Application granted granted Critical

2008-11-10 Publication of EG24228A publication Critical patent/EG24228A/xx

Links

239000008194 pharmaceutical composition Substances 0.000 title 1
150000003892 tartrate salts Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Addiction (AREA)
Diabetes (AREA)
Nutrition Science (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Virology (AREA)
Psychology (AREA)
Cardiology (AREA)
Hematology (AREA)
Hospice & Palliative Care (AREA)
Dermatology (AREA)
AIDS & HIV (AREA)
Child & Adolescent Psychology (AREA)
Oncology (AREA)
Endocrinology (AREA)
Tropical Medicine & Parasitology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)

EG20020483A 2001-05-14 2002-05-13 Tartrate salts of 5,8,18-trizatetracyclo[010.3.1.0.0]hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof EG24228A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US29086101P	2001-05-14	2001-05-14

Publications (1)

Publication Number	Publication Date
EG24228A true EG24228A (en)	2008-11-10

Family

ID=23117845

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EG20020483A EG24228A (en)	2001-05-14	2002-05-13	Tartrate salts of 5,8,18-trizatetracyclo[010.3.1.0.0]hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof

Country Status (47)

Country	Link
US (2)	US6890927B2 (fr)
EP (1)	EP1392307B1 (fr)
JP (1)	JP3779682B2 (fr)
KR (1)	KR100551184B1 (fr)
CN (1)	CN100370987C (fr)
AP (1)	AP1473A (fr)
AR (1)	AR033635A1 (fr)
AT (1)	ATE302607T1 (fr)
AU (1)	AU2002253482B2 (fr)
BG (1)	BG66408B1 (fr)
BR (1)	BR0209605A (fr)
CA (1)	CA2447405C (fr)
CR (1)	CR7080A (fr)
CZ (1)	CZ304763B6 (fr)
DE (1)	DE60205742T2 (fr)
DK (1)	DK1392307T3 (fr)
DO (1)	DOP2002000392A (fr)
EA (1)	EA005528B1 (fr)
EC (2)	ECSP034850A (fr)
EE (1)	EE05441B1 (fr)
EG (1)	EG24228A (fr)
ES (1)	ES2246396T3 (fr)
GE (1)	GEP20053712B (fr)
GT (1)	GT200200084A (fr)
HR (1)	HRP20030910B1 (fr)
HU (1)	HU229867B1 (fr)
IL (2)	IL157933A0 (fr)
IS (1)	IS2217B (fr)
MA (1)	MA27020A1 (fr)
ME (1)	ME00466B (fr)
MX (1)	MXPA03010364A (fr)
MY (1)	MY127807A (fr)
NO (1)	NO326148B1 (fr)
NZ (1)	NZ528210A (fr)
OA (1)	OA12599A (fr)
PA (1)	PA8545101A1 (fr)
PE (1)	PE20021065A1 (fr)
PL (1)	PL214876B1 (fr)
PT (1)	PT1392307E (fr)
RS (1)	RS50814B (fr)
SI (1)	SI1392307T1 (fr)
SK (1)	SK287170B6 (fr)
TN (1)	TNSN03113A1 (fr)
TW (1)	TWI262078B (fr)
UA (1)	UA73422C2 (fr)
WO (1)	WO2002092089A1 (fr)
ZA (1)	ZA200307235B (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RS50069B (sr) *	1997-12-31	2009-01-22	Pfizer Products Inc.,	Aril kondenzovana azapoliciklična jedinjenja
WO2003045437A1 (fr)	2001-11-30	2003-06-05	Pfizer Products Inc.	Compositions pharmaceutiques de 5,7,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene
WO2004103372A1 (fr) *	2003-05-20	2004-12-02	Pfizer Products Inc.	Compositions pharmaceutiques a base de varenicline
EP1694686A1 (fr) *	2003-12-19	2006-08-30	Takeda San Diego, Inc.	Inhibiteurs de kinase
US20050250829A1 (en) *	2004-04-23	2005-11-10	Takeda San Diego, Inc.	Kinase inhibitors
WO2006011955A1 (fr) *	2004-06-30	2006-02-02	Eli Lilly And Company	I (INDOLE-6-CARBONYLE-D-PHÉNYLGLYCINYLE) -4- (L-MÉTHYLPIPÉRIDINe-4-YL) PIPÉRAZINE D- TARTRATE
WO2006023931A2 (fr) *	2004-08-18	2006-03-02	Takeda San Diego, Inc.	Inhibiteurs de kinase
MX2007004495A (es) *	2004-10-15	2007-05-10	Pfizer Prod Inc	Composiciones y procedimientos para la administracion intranasal, bucal, sublingual y pulmonar de vareniclina.
EP1812439B2 (fr) *	2004-10-15	2017-12-06	Takeda Pharmaceutical Company Limited	Inhibiteurs de kinase
MX2007010375A (es) *	2005-02-24	2007-09-25	Pfizer Prod Inc	Preparacion de quinoxalina sustituida de elevada pureza.
US20110086086A1 (en) *	2005-07-26	2011-04-14	Pfizer Inc	Transdermal system for varenicline
US8119655B2 (en) *	2005-10-07	2012-02-21	Takeda Pharmaceutical Company Limited	Kinase inhibitors
MX2007012605A (es) *	2006-02-21	2008-01-11	Teva Pharma	Formas cristalinas novedosas de armodafinil y preparacion de ellas.
EP2223925A1 (fr) *	2006-10-09	2010-09-01	Takeda Pharmaceutical Company Limited	Inhibiteurs de kinase
SG158147A1 (en)	2006-10-09	2010-01-29	Takeda Pharmaceutical	Kinase inhibitors
EP2086977A2 (fr) *	2006-11-09	2009-08-12	Pfizer Products Inc.	Polymorphes d'intermédiaires nicotiniques
US20090062257A1 (en) *	2007-08-29	2009-03-05	Protia, Llc	Deuterium-enriched varenicline
WO2009045488A2 (fr) *	2007-10-02	2009-04-09	Teva Pharmaceutical Industries Ltd.	Nouvelles formes cristallines d'armodafinil et procédé d'élaboration
US20090215787A1 (en) *	2008-02-22	2009-08-27	Mai De Ltd.	Preparations of new polymorphic forms of varenicline tartrate
WO2009111623A2 (fr) *	2008-03-06	2009-09-11	Dr. Reddy's Laboratories Ltd.	Tartrate de varénicline amorphe
WO2009109651A1 (fr) *	2008-03-06	2009-09-11	Medichem, S.A.	Sels d'un dérivé de pyrazino[2,3-h][3]benzazépine
WO2009146031A1 (fr)	2008-03-31	2009-12-03	University Of South Florida	Méthodes de traitement d'une ataxie et d'un déséquilibre non-ataxique induits par une maladie
US8039620B2 (en)	2008-05-22	2011-10-18	Teva Pharmaceutical Industries Ltd.	Varenicline tosylate, an intermediate in the preparation process of varenicline L-tartrate
US20090318460A1 (en) *	2008-05-26	2009-12-24	Glenmark	Amorphous varenicline tartrate and process for the preparation thereof
US20090318695A1 (en) *	2008-06-19	2009-12-24	Vinod Kumar Kansal	Processes for the preparation of varenicline and intermediates thereof
WO2010005643A1 (fr) *	2008-07-10	2010-01-14	Teva Pharmaceutical Industries Ltd.	Procédés de purification du sel l-tartrate de varénicline et préparation de formes cristallines du sel l-tartrate de varénicline
US8314235B2 (en) *	2008-09-01	2012-11-20	Actavis Group Ptc Ehf	Process for preparing varenicline, varenicline intermediates, pharmaceutically acceptable salts thereof
WO2010143070A2 (fr)	2009-06-10	2010-12-16	Actavis Group Ptc Ehf	Co-précipités amorphes de tartrate de varénicline
EP2438054A1 (fr) *	2009-06-22	2012-04-11	Teva Pharmaceutical Industries Ltd.	Formes solides des sels de varénicline et leurs procédés de préparation
EP2545054A1 (fr)	2010-03-09	2013-01-16	Actavis Group Ptc Ehf	Varénicline de haute pureté ou son sel pharmaceutiquement acceptable sensiblement exempt d'impureté méthylvarénicline
WO2011140431A1 (fr)	2010-05-06	2011-11-10	Teva Pharmaceutical Industries Ltd.	Sels de la varénicline et leurs formes cristallines
WO2013163917A1 (fr)	2012-04-13	2013-11-07	连云港金康和信药业有限公司	Composé jk12a et sa préparation
KR101663550B1 (ko) *	2014-06-11	2016-10-07	조선대학교산학협력단	주석산을 유효성분으로 포함하는 고혈압 예방 또는 치료용 약학조성물 및 건강기능식품
KR101724301B1 (ko)	2016-11-22	2017-04-10	주식회사 한서켐	바레니클린 살리실산염의 i형 결정 및 그 제조방법
WO2018154395A2 (fr)	2018-06-11	2018-08-30	Alvogen Malta Operations (Row) Ltd	Composition pharmaceutique à libération contrôlée de varénicline
WO2021092275A1 (fr)	2019-11-06	2021-05-14	Children’S National Medical Center	Procédés et compositions pour la prévention et le traitement d'une lésion de reperfusion ischémique et d'une infection
ES3039903T3 (en)	2020-04-28	2025-10-27	Oyster Point Pharma Inc	Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections
US20240374609A1 (en) *	2021-08-20	2024-11-14	Viwit Pharmaceuticalco., Ltd.	Nitrosamine impurity, varenicline pharmaceutical composition capable of reducing generation of nitrosamine impurities and preparation and use thereof
KR20230068877A (ko)	2021-11-11	2023-05-18	주식회사 아울바이오	고용량 바레니클린을 포함하는 미립구 및 이의 제조방법 및 이를 포함하는 약학적 조성물
CN113980020B (zh) *	2021-11-22	2023-05-09	浙江车头制药股份有限公司	一种酒石酸伐尼克兰晶型的制备方法
EP4452236A2 (fr)	2021-12-23	2024-10-30	Medichem, S.A.	Formulations pharmaceutiques solides de varénicline
EP4241775A1 (fr)	2022-03-11	2023-09-13	Par Pharmaceutical, Inc.	Comprimé de varénicline et son procédé de fabrication
US11602537B2 (en)	2022-03-11	2023-03-14	Par Pharmaceutical, Inc.	Varenicline compound and process of manufacture thereof
WO2023244574A1 (fr)	2022-06-14	2023-12-21	Amygdala Neurosciences, Inc.	Composés inhibiteurs d'aldh-2 et procédés d'utilisation
WO2024095172A1 (fr)	2022-11-04	2024-05-10	Pfizer Inc.	Promédicaments de varénicline et composés contenant des amines vulnérables
KR20240115109A (ko)	2023-01-18	2024-07-25	주식회사 아울바이오	고용량 바레니클린을 포함하는 미립구 및 이의 제조방법 및 이를 포함하는 약학 조성물
IT202300003888A1 (it)	2023-03-03	2024-09-03	Dipharma Francis Srl	Processo di preparazione di un farmaco usato per trattare la dipendenza da nicotina
WO2024224270A1 (fr)	2023-04-24	2024-10-31	Pfizer Inc.	Formulations de varénicline

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3471503A (en)	1967-05-05	1969-10-07	Mcneilab Inc	1,2,3,5,6,7-hexahydro-4-phenethyl-2,6-methano-4h-4- benzazonin-12-ols
RS50069B (sr) *	1997-12-31	2009-01-22	Pfizer Products Inc.,	Aril kondenzovana azapoliciklična jedinjenja
IL137937A0 (en) *	1999-08-27	2001-10-31	Pfizer Prod Inc	A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
YU34501A (sh) *	2000-05-26	2003-10-31	Pfizer Products Inc.	Postupak reaktivne kristalizacije radi povećanja veličine čestica

2002
- 2002-04-26 GE GE5341A patent/GEP20053712B/en unknown
- 2002-04-26 OA OA1200300289A patent/OA12599A/en unknown
- 2002-04-26 EP EP02722625A patent/EP1392307B1/fr not_active Expired - Lifetime
- 2002-04-26 DE DE60205742T patent/DE60205742T2/de not_active Expired - Lifetime
- 2002-04-26 KR KR1020037014754A patent/KR100551184B1/ko not_active Expired - Lifetime
- 2002-04-26 SI SI200230189T patent/SI1392307T1/sl unknown
- 2002-04-26 MX MXPA03010364A patent/MXPA03010364A/es active IP Right Grant
- 2002-04-26 HR HR20030910A patent/HRP20030910B1/xx not_active IP Right Cessation
- 2002-04-26 EA EA200301121A patent/EA005528B1/ru active Protection Beyond IP Right Term
- 2002-04-26 ME MEP-2008-717A patent/ME00466B/fr unknown
- 2002-04-26 JP JP2002589006A patent/JP3779682B2/ja not_active Expired - Lifetime
- 2002-04-26 CZ CZ2003-2916A patent/CZ304763B6/cs not_active IP Right Cessation
- 2002-04-26 SK SK1336-2003A patent/SK287170B6/sk not_active IP Right Cessation
- 2002-04-26 RS YUP-867/03A patent/RS50814B/sr unknown
- 2002-04-26 WO PCT/IB2002/001437 patent/WO2002092089A1/fr not_active Ceased
- 2002-04-26 PT PT02722625T patent/PT1392307E/pt unknown
- 2002-04-26 IL IL15793302A patent/IL157933A0/xx unknown
- 2002-04-26 NZ NZ528210A patent/NZ528210A/en not_active IP Right Cessation
- 2002-04-26 EE EEP200300556A patent/EE05441B1/xx unknown
- 2002-04-26 CA CA002447405A patent/CA2447405C/fr not_active Expired - Lifetime
- 2002-04-26 AT AT02722625T patent/ATE302607T1/de active
- 2002-04-26 UA UA20031110266A patent/UA73422C2/uk unknown
- 2002-04-26 PL PL366551A patent/PL214876B1/pl unknown
- 2002-04-26 CN CNB028099125A patent/CN100370987C/zh not_active Expired - Lifetime
- 2002-04-26 DK DK02722625T patent/DK1392307T3/da active
- 2002-04-26 HU HU0304088A patent/HU229867B1/hu unknown
- 2002-04-26 BR BR0209605-6A patent/BR0209605A/pt not_active IP Right Cessation
- 2002-04-26 AU AU2002253482A patent/AU2002253482B2/en not_active Expired
- 2002-04-26 ES ES02722625T patent/ES2246396T3/es not_active Expired - Lifetime
- 2002-05-06 DO DO2002000392A patent/DOP2002000392A/es unknown
- 2002-05-06 US US10/139,730 patent/US6890927B2/en not_active Expired - Lifetime
- 2002-05-09 AP APAP/P/2002/002523A patent/AP1473A/en active
- 2002-05-10 GT GT200200084A patent/GT200200084A/es unknown
- 2002-05-10 PE PE2002000391A patent/PE20021065A1/es active IP Right Grant
- 2002-05-10 MY MYPI20021696A patent/MY127807A/en unknown
- 2002-05-13 AR ARP020101734A patent/AR033635A1/es active IP Right Grant
- 2002-05-13 TW TW091109919A patent/TWI262078B/zh not_active IP Right Cessation
- 2002-05-13 EG EG20020483A patent/EG24228A/xx active
- 2002-05-14 PA PA20028545101A patent/PA8545101A1/es unknown
2003
- 2003-07-08 TN TNPCT/IB2002/001437A patent/TNSN03113A1/fr unknown
- 2003-09-15 IS IS6957A patent/IS2217B/is unknown
- 2003-09-15 IL IL157933A patent/IL157933A/en active IP Right Grant
- 2003-09-16 ZA ZA200307235A patent/ZA200307235B/en unknown
- 2003-09-22 CR CR7080A patent/CR7080A/es not_active Application Discontinuation
- 2003-11-10 MA MA27389A patent/MA27020A1/fr unknown
- 2003-11-11 BG BG108343A patent/BG66408B1/bg unknown
- 2003-11-13 NO NO20035036A patent/NO326148B1/no not_active IP Right Cessation
- 2003-11-14 EC EC2003004850A patent/ECSP034850A/es unknown
- 2003-11-14 EC EC2003004849A patent/ECSP034849A/es unknown
2005
- 2005-02-28 US US11/069,724 patent/US7265119B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
MXPA03010364A (es)	2004-03-16
CZ304763B6 (cs)	2014-10-01
NO326148B1 (no)	2008-10-06
NO20035036D0 (no)	2003-11-13
EP1392307B1 (fr)	2005-08-24
US20050148591A1 (en)	2005-07-07
CA2447405C (fr)	2006-10-17
IS6957A (is)	2003-09-15
AU2002253482B2 (en)	2007-09-06
HUP0304088A3 (en)	2011-11-28
JP2004533446A (ja)	2004-11-04
AP2002002523A0 (en)	2002-06-30
UA73422C2 (en)	2005-07-15
IS2217B (is)	2007-03-15
CZ20032916A3 (cs)	2004-09-15
MA27020A1 (fr)	2004-12-20
US6890927B2 (en)	2005-05-10
SK287170B6 (sk)	2010-02-08
TWI262078B (en)	2006-09-21
EP1392307A1 (fr)	2004-03-03
NO20035036L (no)	2003-11-13
MY127807A (en)	2006-12-29
WO2002092089A1 (fr)	2002-11-21
ECSP034849A (es)	2003-12-24
PA8545101A1 (es)	2003-09-05
US20030166701A1 (en)	2003-09-04
BG66408B1 (bg)	2014-01-31
EA200301121A1 (ru)	2004-02-26
DK1392307T3 (da)	2005-11-07
HU229867B1 (en)	2014-10-28
HK1062645A1 (en)	2004-11-19
BG108343A (bg)	2004-12-30
KR20040010638A (ko)	2004-01-31
ME00466B (fr)	2011-10-10
CN1509174A (zh)	2004-06-30
HRP20030910A2 (en)	2004-02-29
DOP2002000392A (es)	2002-11-15
ES2246396T3 (es)	2006-02-16
KR100551184B1 (ko)	2006-02-13
AR033635A1 (es)	2003-12-26
PL366551A1 (en)	2005-02-07
ATE302607T1 (de)	2005-09-15
AP1473A (en)	2005-09-30
TNSN03113A1 (fr)	2005-12-23
ECSP034850A (es)	2003-12-24
DE60205742T2 (de)	2006-05-11
EA005528B1 (ru)	2005-04-28
HUP0304088A2 (hu)	2004-04-28
HRP20030910B1 (hr)	2011-11-30
SK13362003A3 (en)	2004-11-03
IL157933A0 (en)	2004-03-28
NZ528210A (en)	2005-04-29
PL214876B1 (pl)	2013-09-30
GEP20053712B (en)	2005-12-26
GT200200084A (es)	2003-09-12
CA2447405A1 (fr)	2002-11-21
PT1392307E (pt)	2005-11-30
CR7080A (es)	2006-08-09
ZA200307235B (en)	2004-09-16
OA12599A (en)	2006-06-08
JP3779682B2 (ja)	2006-05-31
CN100370987C (zh)	2008-02-27
SI1392307T1 (sl)	2005-12-31
EE200300556A (et)	2004-04-15
EE05441B1 (et)	2011-08-15
PE20021065A1 (es)	2002-11-21
BR0209605A (pt)	2004-03-23
IL157933A (en)	2013-07-31
YU86703A (sh)	2006-05-25
DE60205742D1 (de)	2005-09-29
US7265119B2 (en)	2007-09-04
RS50814B (sr)	2010-08-31

Publication	Publication Date	Title
EG24228A (en)	2008-11-10	Tartrate salts of 5,8,18-trizatetracyclo[010.3.1.0.0]hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
IL161857A0 (en)	2005-11-20	Pharmaceutical compositions of 5,7,14-triazatetracycloÄ10.3.1.0(2,11).0(4,9)Ü-hexadeca-2(11)3,5,7,9-pentaene
PL374325A1 (en)	2005-10-17	Succinic acid salts of 5,8,14-triazatetracyclo[10.3.1.0 2,11 .0 4,9 ]-hexadeca-2(11),3,5,7,9,-pentaene and pharmaceutical compositions thereof
HUP0303148A3 (en)	2009-08-28	4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, pharmaceutical compositions containing the compounds and processes for their preparation
HUP0401567A3 (en)	2005-06-28	Novel 4,5-dyhydro-1h-pyrazole derivatives having cb1-antagonistic activity, their use and pharmaceutical compositions containing them
HUP0400246A3 (en)	2009-12-28	1,2,4-trioxolane antimalarial pharmaceutical compositions and process for their preparation and use
HUP0402113A3 (en)	2012-05-29	4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, preparation and use thereof
HUP0300207A3 (en)	2005-07-28	1,2,3,4-tetrahydroisquinoline derivatives, pharmaceutical compositions containing them and their preparation processes
HUP0400467A3 (en)	2012-08-28	2-iminopyrrolidine derivatives, pharmaceutical compositions containing them and their use
HUP0302656A3 (en)	2009-08-28	Fumaric acid amides, their use for preparation of pharmaceutical compositions and pharmaceutical compositions containing the compounds
SI1417206T1 (sl)	2010-09-30	Novi H piridazin onski derivati farmacevtski sestavki ki jih vsebujejo in postopek za pripravo aktivne sestavine
HUP0304085A3 (en)	2005-09-28	The citrate salt of 5,8,14-triazatetracyclo(10.3.1.02,11.04,9)-hexadeca-2.(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
HUP0400179A3 (en)	2004-10-28	2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines, their use and pharmaceutical compositions containing them
HUP0401403A3 (en)	2005-11-28	2,4-diaminothiazole derivatives, their use and pharmaceutical compositions containing them
HUP0500024A3 (en)	2009-01-28	6-aminomorphinane derivatives, their use and pharmaceutical compositions containing them
HUP0302193A3 (en)	2012-02-28	1,4-diazabicyclo[3.2.2]nonabenzoxazole, -benzothiazole and benzimidazole derivatives, preparation thereof and pharmaceutical compositions containing them
HUP0401369A3 (en)	2006-05-29	Pharmaceutical formulation comprising (r)-bicalutamide, process for its preparation and use thereof
HUP0401713A3 (en)	2012-08-28	Aralkyl-tetrahydro-pyridines, their preparation and pharmaceutical compositions containing same
HUP0401773A3 (en)	2005-06-28	Use of [(2-amino-3,4-dioxo-1cyclobuten-1-yl)amino]alkanacid derivatives for the preparation pharmaceutical compositions usable for treatment of pain
AU2002360117A1 (en)	2003-07-03	Aralkyl-tetrahydro-pyridines, their preparation and pharmaceutical compositions containing same
IL158587A0 (en)	2004-05-12	Novel 5-thio-ss-d-xylopyranoside derivatives, preparation method thereof, pharmaceutical compositions containing same and the therapeutic use thereof
HUP0303455A3 (en)	2005-06-28	Imidazolidine derivatives, their preparation and pharmaceutical compositions containing them
HUP0402149A3 (en)	2005-08-29	Water-soluble phenylpyridazine derivatives, their use and pharmaceutical compositions containing the same
AU2002308369A1 (en)	2002-09-24	1-butane acid derivatives, pharmaceutical compositions containing said derivatives and the use thereof
HUP0303482A3 (en)	2012-12-28	Mercaptoacetylamide derivatives, process for their preparation and their use and pharmaceutical compositions containing them